OACC logo

Oaktree Acquisition Corp III Life Sciences

OACC

Build a strategy around OACC

Accountable AI Logo

Oaktree Acquisition Corp III Life Sciences AI Insights

Informational only. Not investment advice.
As of 2025-12-11

Snapshot

  • SPAC with zero revenue - entire 2.0M net income TTM from 2.2M interest on trust assets. Operating loss of 226K from G&A.[Interest Income]
  • Trading at 1.35x P/B with 7.85 book value per share. 193M equity vs 260M market cap implies 35% premium to NAV.[Price to Book Ratio]
  • Near-zero debt (12K) with 1.3M cash outside trust. Burn rate of 226K/yr G&A gives ~6 years runway before trust access needed.[Cash and Cash Equivalents]

Watch Triggers

  • Price to Book Ratio: Falls below 1.05xSignals market losing confidence in deal; approaching redemption floor creates entry point
  • Cash and Cash Equivalents: Drops below 500KWould indicate accelerating burn or extension costs; trust access timeline pressure
  • Volume: Spikes above 100K dailyUnusual activity often precedes deal announcement or material news

Bull Case

Oaktree sponsor pedigree and 193M trust capital positioned for life sciences deal. Premium to NAV (1.35x P/B) reflects deal optionality value.

Price to Book RatioCommon Stockholders Equity

Minimal cash burn (226K G&A TTM) preserves trust value. Interest income (2.2M) exceeds operating costs by 10x, growing NAV.

Interest IncomeGeneral and Administrative Expense

Bear Case

35% premium to NAV creates immediate downside if no deal materializes. Redemption at ~7.85/share vs 10.58 market price = 26% loss risk.

Price to Book RatioBook Value Per Share

Ultra-low volume (2,926 shares TTM) creates liquidity trap. Position sizing severely constrained; exit may require significant discount.

Volume

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
35%

Leverage OACC's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

SPAC value hinges entirely on deal announcement - current premium suggests market expects target within 12m

3-12mlow
  • Life sciences focus limits target universe
  • Oaktree sponsor reputation for deal sourcing
  • 35% NAV premium prices in deal optionality
P/B 1.35x vs typical SPAC 1.0x NAV193M trust available for acquisitionZero operating business currently

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.